Please provide your email address to receive an email when new articles are posted on . The addition of post-transplant cyclophosphamide to sirolimus and cyclosporine reduced chronic GVHD. Efforts are ...
First successful allogeneic stem cell transplant using deceased donor in blood cancer clinical trial
For the first time ever, a patient has received an allogeneic stem cell transplant using a deceased donor graft as part of a blood cancer clinical trial at Huntsman Cancer Institute at the University ...
As part of consolidation therapy, patients may receive allogenic hematopoietic stem cell transplantation (HCT). HCT involves the replacement of a patient's normal source of bone marrow cells by ...
Stem cell transplants remain essential for blood cancers, with expanded donor options including half-matched family members and umbilical cord blood. Cyclophosphamide has improved graft-versus-host ...
Plans to expand clinical program and uplist to the NASDAQ were also presented. NEW YORK, NY / ACCESS Newswire / May 21, 2026 /Cell Source, Inc. (OTC PINK:CLCS) ("Cell Source" or the "Company"), a ...
Allogeneic HSCT achieved 92% sustained, medication-free remission and 100% survival in children with monogenic IBD, highlighting its potential as a transformative treatment. Monogenic IBD, ...
In preclinical studies, researchers found that priming the immune system with a Treg-expanding therapy before stem cell transplant boosted survival, protected vital organs, and promoted a balanced gut ...
A research team from the Department of Medicine, School of Clinical Medicine, LKS Faculty of Medicine, the University of Hong ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results